460 results about "Whole blood units" patented technology

A biosensor in the form of a strip. In one embodiment, the biosensor strip comprises an electrode support, a first electrode, i.e., a working electrode, a second electrode, i.e., a counter electrode, and a third electrode, i.e., a reference electrode. Each of the electrodes is disposed on and supported by the electrode support. Each of the electrodes is spaced apart from the other two electrodes. The biosensor strip can include a covering layer, which defines an enclosed space over the electrodes. This enclosed space includes a zone where an analyte in the sample reacts with reagent(s) deposited at the working electrode. This zone is referred to as the reaction zone. The covering layer has an aperture for receiving a sample for introduction into the reaction zone. The biosensor strip can also include at least one layer of mesh interposed in the enclosed space between the covering layer and the electrodes in the reaction zone. This layer of mesh facilitates transporting of the sample to the electrodes in the reaction zone. In another embodiment, a biosensor strip can be constructed to provide a configuration that will allow the sample to be introduced to the reaction zone by action of capillary force. In this embodiment, the layer of mesh can be omitted. The invention also provides a method for determining the concentration of glucose in a sample of whole blood by using the biosensor of this invention.

A CCI-779 oral dosage form is provided in which, after oral administration to a subject, the CCI-779 has a whole blood peak concentration (C_max) of 5.4±1.8 ng/mL and an area under the curve (AUC) of about 66±about 22 ng-hr/ml and the sirolimus has a C_max of 18.7±9.6 ng/mL and an AUC of about 600±about 228 ng-hr/ml, for a 25 mg unit dose of CCI-779. Another CCI-779 oral dosage form is provided which, after oral administration thereof to a subject, the CCI-779 has a C_max of 5.7±1.7 ng/mL and an AUC of about 60±about 20 ng-hr/ml and the sirolimus has a C_max of 17.1±8.1 ng/mL and an AUC of about 548±about 187 ng-hr/ml in whole blood, for a 25 mg unit dose of CCI-779. Products containing these oral dosage forms, and methods of use thereof, are also described.

The invention relates to an integrated microfluidic chip for capture of cancer cells in whole blood. The integrated microfluidic chip for capture of cancer cells in whole blood comprises three inlets, an erythrocyte lysis unit, a leucocyte capture unit, a cancer cell capture unit and an outlet, wherein the three inlets, the erythrocyte lysis unit, the leucocyte capture unit, the cancer cell capture unit and the outlet are connected orderly. The leucocyte capture unit comprises a first diverter, a soft magnetic microcolumn array and permanent magnets. The first diverter is connected with the soft magnetic microcolumn array. The permanent magnets are arranged at two sides of the soft magnetic microcolumn array. The cancer cell capture unit comprises a second diverter and a capture microstructure array, wherein the second diverter and the capture microstructure array are connected orderly. Compared with the prior art, the integrated microfluidic chip for capture of cancer cells in whole blood has the advantages of high integration degree, simple operation, high cell capture efficiency, simple manufacture processes and the like.

A system for laser scanning provides spectral flexibility needed for the spectroscopic monitoring of highly multiplexed samples, such as cellular and particle assays in whole blood or other suspensions. In accordance with embodiments of the present invention, the system comprises a scanner to direct an excitation laser through a sample, an objective to collect light emitted by the sample in response to the excitation laser, a spectrograph to disperse the emitted light over a plurality of wavelengths as a spectrum, and a charge coupled device for detecting the spectrum. The system can be used with samples having a variety of reporter tags, including one or more SERS tags, fluorescent organic and protein tags, and quantum dot tags. A laser scanning apparatus and method of using the same is also provided.

A device for separating plasma from whole blood is provided having an evacuated primary collection chamber capable of fluid communication through a porous filter to an evacuated secondary collection chamber. An agglutinating agent is provided within the primary collection chamber so as to aggregate blood cells within a whole blood sample. The porous filter has a pore size which is small enough to capture the aggregated blood cells therein, yet large enough to permit plasma to transfer therethrough under pressures associated with conventional evacuated blood collection tubes. The primary and secondary collection chambers may be provided in separate containers or tubes, with transfer occurring therebetween through a transfer device including the porous filter therein.

Disclosed in one aspect is a method for performing a complete blood count (CBC) on a sample of whole blood by metering a predetermined amount of the whole blood and mixing it with a predetermined amount of diluent and stain and transferring a portion thereof to an imaging chamber of fixed dimensions and utilizing an automated microscope with digital camera and cell counting and recognition software to count every white blood cell and red blood corpuscle and platelet in the sample diluent/stain mixture to determine the number of red cells, white cells, and platelets per unit volume, and analyzing the white cells with cell recognition software to classify them.

The invention discloses a construction method of a ctDNA ultra-low-frequency mutation detection library, a kit and an analysis method of library detection data. The construction method comprises steps as follows: S1, cfDNA is extracted from whole blood; S2, the terminal of cfDNA is restored and an A basic group is added to the 3'terminal; S3, the terminal of the cfDNA obtained in S2 is connected with connectors containing random label sequences; S4, primers for multiplex PCR (polymerase chain reaction) are designed according to the sequences of the connectors and an object region for object region capturing; S5, a PCR product in S4 is subjected to magnetic bead purification, and small-fragment DNA not subjected to non-specific amplification and primer dimer are removed; S6, a product in S5 is subjected to PCR amplification, an index sequence is introduced, and the ctDNA ultra-low-frequency mutation library is obtained. According to the method, PCR mistakes and sequencing mistakes are eliminated, and the detection specificity is improved.

A method and apparatus that allows accurate spectrophotometric determination of the concentrations of various hemoglobin species in whole undiluted blood. The invention employs 1) an optical apparatus designed to maximize the true optical absorbance of whole blood and to minimize the effects of light scattering on the spectrophotometric measurements of the concentrations of various constituent components, and 2) methods to correct the hemoglobin concentration measurements for light scattering and for the effects of the finite bandwidth of the substantially monochromatic light. In the optical apparatus optical parameters, such as sample thickness, detector size and shape, sample-to-detector distance, wavelengths, monochromicity, and maximum angle of light capture by detector, are selected so as to minimize the contribution of light scattering to maximize the contribution of true optical absorbance. After making measurements of a blood sample's optical density at each of the wavelengths, corrections are made for the effects of light scattering.

A membrane separation device is disclosed along with systems and methods employing the device in blood processing procedures. In one embodiment, a spinning membrane separator is provided in which at least two zones or regions are created in the gap between the membrane and the shell, such that mixing of the fluid between the two regions is inhibited by a radial rib associated with the membrane that decreases the gap between the membrane and the shell to define two fluid regions, the ridge isolating the fluid in the two regions to minimize mixing between the two. Automated systems and methods are disclosed for separating a unit of previously collected whole blood into components, such as concentrated red cells and plasma, for collecting red cells and plasma directly from a donor in a single pass, and for cell washing. Data management systems and methods and priming methods are also disclosed.

The invention discloses a method for preparing a polyvinylidene fluoride affinity membrane using amino acid as a ligand. The affinity membrane is prepared by hydrophilically modifying a polyvinylidene fluoride hollow fiber membrane and grafting the amino acid ligand. The grafting amount of the amino acid is 150 to 250mg/g for each membrane. The invention also discloses application of the affinity membrane in removing endotoxin in blood plasma, which removes the endotoxin in the blood plasma by a dynamic absorption means. The polyvinylidene fluoride affinity membrane prepared by the method has stable performance, good bio-compatibility and high endotoxin removing efficiency, and can be used for whole blood perfusion as well as blood plasma perfusion.

A lateral flow immunoassay featuring encapsulated metal particles. The encapsulated particles may use SERS nanotags as the detection modality. The use of encapsulated particles as a detection modality, in particular encapsulated SERS tags increases the sensitivity of an LFI prepared for visual reading and introduces the ability to obtain substantially more sensitive qualitative results or quantitative results through the analysis of a SERS spectrum read from an LFI prepared in accordance with the present invention. The use of SERS as detection modality also enhances the ability of an LFI device to be used for a multiplexed test. Other aspects of the present invention include LFI devices specifically configured to test whole blood, a reader for the detection and interpretation of a multiplexed assay and the hardware and software components used to implement the reader.

The invention discloses a whole blood CRP detection apparatus, a method thereof, and a blood cell analyzer. The apparatus comprise a syringe unit, a weak solution distribution unit, a DIFF channel measuring unit, a reagent unit, a counting chamber unit, a sampling needle, a negative pressure chamber and a waste liquid discharge unit; the reagent unit comprises a weak solution, a WBC reagent, a DIFF reagent and a second CRP reagent; and the counting chamber unit comprises a CRP pool, a DIFF pool, a WBC pool and an RBC pool, and is used for completing a reaction of a CRP channel sample with the CRP reagent, a reaction of a DIFF channel sample with the DIFFC reagent, a reaction of a WBC channel sample with the WBC reagent and a reaction of an RBC channel sample with a reagent. The apparatus and the method can be used to simultaneously detect CRP and five-classifications blood routine examination, and have the characteristics of parallel detection of all detection channels, and fast test speed.

An analyzer, preferably a desktop analyzer, includes: a component transport system; a liquid dispense or aspirating station; a member removably located on the transport system. The removable holder includes: a probe tip dispenser; a fluid supply section for holding a sample; a test element recess for holding one or more test elements or test element holders, wherein the removable holder is configured to contain the test element recess such that a test element can be acted upon by the liquid dispense or aspirating station, while the test element is in the recess; and a measurement device to analyze a sample. Another aspect provides a removable centrifuge model on the transport system, which separates samples, such as whole blood before analysis.